Liposomal doxorubicin (TLC D99, myocet) in combination with cyclophosphamide (C), vincristine (O) and prednisone (P) for aggressive non-Hodgkin's lymphomas (NHL).

被引：0
|
作者：
Levine, A
Tulpule, A
Espina, B
Buchanan, L
Africano, M
Welles, L
机构：
[1] Univ So Calif, Norris Canc Hosp, Los Angeles, CA USA
[2] Med Res, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
478P
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [31] Rituximab and infusional cyclophosphamide, doxorubicin and etoposide (cde) in combination with haart: a safe and highly active regimen in HIV-related non-Hodgkin's lymphomas (NHL)
    Spina, Michele
    Simonelli, Cecilia
    Vaccher, Emanuela
    Rossi, Giuseppe
    Jaeger, Ulrich
    Sparano, Joseph A.
    Tirelli, Umberto
    ANNALS OF ONCOLOGY, 2004, 15 : 153 - 153
  • [32] RITUXIMAB AND INFUSIONAL CYCLOPHOSPHAMIDE, DOXORUBICIN AND ETOPOSIDE (CDE) IN COMBINATION WITH HAART: A SAFE AND HIGHLY ACTIVE REGIMEN IN HIV-RELATED NON-HODGKIN'S LYMPHOMAS (NHL)
    Spina, Michele
    Vaccher, Emanuela
    Lleshi, Arben
    Morra, Aldo
    Rossi, Giuseppe
    Jaeger, Ulrich
    Sparano, Joseph
    Tirelli, Umberto
    ANNALS OF ONCOLOGY, 2004, 15 : 81 - 82
  • [33] Rituximab and infusional cyclophosphamide, doxorubicin and etoposide (CDE) in combination with HAART: A safe and highly active regimen in HIV-related non-Hodgkin's lymphomas (NHL).
    Spina, M
    Simonelli, C
    Vaccher, E
    Rossi, G
    Jaeger, U
    Sparano, JA
    Tirelli, U
    BLOOD, 2003, 102 (11) : 123A - 123A
  • [34] Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma - A multicenter phase II study
    Bergmann, L
    Karakas, T
    Lautenschlager, G
    Jager, E
    Knuth, A
    Mitrou, PS
    Hoelzer, D
    ANNALS OF ONCOLOGY, 1995, 6 (10) : 1019 - 1024
  • [35] Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100) - A phase II study
    Basaran, M
    Bavbek, ES
    Sakar, B
    Eralp, Y
    Alici, S
    Tas, F
    Yaman, F
    Dogan, O
    Camlica, H
    Onat, H
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (06): : 570 - 575
  • [36] Efficacy of fludarabine, mitoxantrone, dexamethasone alternating with cyclophosphamide, doxorubicin, vincristine and prednisone (FMD/CHOP) in bulky follicular non-Hodgkin's lymphoma
    Wilder, DD
    Ogden, JL
    Jain, VK
    BLOOD, 2001, 98 (11) : 603A - 603A
  • [37] Intermediate and high grade non-Hodgkin's lymphoma (IHG NHL) in the elderly with favorable physiologic index.: A phase II study of CEVOP combination [cyclophosphamide (C), epirubicin (E), oral etoposide (V), vincristine (O) and prednisone (P)].
    Soubeyran, P
    Monnereau, A
    Eghbali, H
    Ceccaldi, J
    Cany, L
    Guichard, P
    Hallé, O
    Rémuzon, P
    Campo, ML
    Hoerni, B
    BLOOD, 2000, 96 (11) : 141A - 141A
  • [38] Granulocyte Colony-Stimulating Factor (GCSF) Use with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone plus /- Rituximab ( CHOP±R) Treatment for Aggressive Non-Hodgkin's Lymphoma (aNHL)
    Kouroukis, Tom
    Cheung, Winson Y.
    Abdel-Samad, Nizar
    Sehdev, Sandeep
    Poulin-Costello, Melanie
    Gillesby, Brad
    Robson, Ewan J. D.
    BLOOD, 2016, 128 (22)
  • [39] Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas
    Mugitani, A
    Tatsumi, Y
    Tanaka, K
    Yasui, Y
    Inoue, T
    ANTICANCER RESEARCH, 1999, 19 (4C) : 3393 - 3397
  • [40] A phase II study of liposomal vincristine in CHOP with rituximab for patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL): A safe and effective combination.
    Rodriguez, MA
    Sarris, A
    East, K
    Dang, NH
    Fayad, L
    Goy, A
    Hagemeister, FB
    McLaughlin, P
    Pro, B
    Romaguera, J
    Samaniego, F
    Younes, A
    Cabanillas, F
    BLOOD, 2002, 100 (11) : 92A - 92A
12345